Proqr Therapeutics N V (PRQR)

Dec 19, 2024

BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Dec 19, 2024

Dec 17, 2024

ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com

Dec 17, 2024

Dec 15, 2024

ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World

Dec 15, 2024

Dec 15, 2024

ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World

Dec 15, 2024

Dec 14, 2024

ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St

Dec 14, 2024

Dec 14, 2024

Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding - Simply Wall St

Dec 14, 2024

Dec 14, 2024

ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Chardan Capital - Defense World

Dec 14, 2024

Dec 13, 2024

Leiden-based biotech company ProQR bags €7.7M - Silicon Canals

Dec 13, 2024

Dec 12, 2024

ProQR shares hold price target, buy rating on RNA tech optimism - Investing.com

Dec 12, 2024

Dec 12, 2024

JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat

Dec 12, 2024

Dec 12, 2024

ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital - MarketBeat

Dec 12, 2024

Dec 12, 2024

ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright - MarketBeat

Dec 12, 2024

Dec 12, 2024

ProQR Therapeutics announces $8.1M in new funding from RSRT - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

RNA specialist ProQR Therapeutics NV bags US$8.1m funding - European Biotechnology News

Dec 12, 2024

Dec 12, 2024

ProQR secures $9.1M for Rett syndrome trial By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

ProQR secures $9.1M for Rett syndrome trial - Investing.com India

Dec 11, 2024

Dec 11, 2024

ProQR Therapeutics Announces $8.1 Million in New Funding - GlobeNewswire

Dec 11, 2024

Dec 11, 2024

ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment - StockTitan

Dec 11, 2024

Dec 10, 2024

ProQR Therapeutics' SWOT analysis: RNA editing stock faces pivotal clinical phase - Investing.com

Dec 10, 2024

Dec 10, 2024

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - The Manila Times

Dec 10, 2024

Dec 10, 2024

ProQR Therapeutics Strengthens RNA Editing Leadership with Key ADAR Expert Appointment - StockTitan

Dec 10, 2024

Dec 06, 2024

ProQR Therapeutics price target raised to $8 from $5 at JMP Securities - Yahoo Finance

Dec 06, 2024

Dec 05, 2024

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 - GlobeNewswire

Dec 05, 2024

Dec 05, 2024

ProQR Therapeutics to Showcase Revolutionary RNA Editing Platform at December Investor Event - StockTitan

Dec 05, 2024

Nov 30, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com - Defense World

Nov 30, 2024

Nov 24, 2024

OneDigital Investment Advisors LLC Boosts Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Nov 24, 2024

Nov 21, 2024

ProQR Therapeutics NV (MEX:PRQR) Earnings Yield % : N/A% (As of Nov. 21, 2024) - GuruFocus.com

Nov 21, 2024

Nov 21, 2024

RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR

Nov 21, 2024

Nov 21, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 21, 2024

Nov 20, 2024

ProQR Therapeutics NV (MEX:PRQR) 50-Day SMA : MXN35.82 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 14, 2024

ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World

Nov 14, 2024

Nov 13, 2024

What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat

Nov 13, 2024

Nov 09, 2024

ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

ProQR: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 08, 2024

Nov 08, 2024

ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat

Nov 08, 2024

Nov 07, 2024

ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com

Nov 07, 2024

Nov 07, 2024

ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK

Nov 07, 2024

Nov 07, 2024

PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 07, 2024

Nov 07, 2024

ProQR Announces Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Nov 07, 2024

Nov 06, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat

Nov 06, 2024

Oct 30, 2024

Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN

Oct 30, 2024

Oct 29, 2024

ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow

Oct 29, 2024

Oct 29, 2024

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat

Oct 29, 2024

Oct 29, 2024

This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga

Oct 29, 2024

Oct 26, 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire

Oct 26, 2024

Oct 25, 2024

ProQR Announces Major Share Offering Agreement - TipRanks

Oct 25, 2024